PDX Portal

Model Details

Patient Information for Model: BCM-15030

Model Contact

Model: BCM-15030
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-15030

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Histology Information for Model: BCM-15030

Patient

PDX

H&E

HER2

Metastasis Information for Model: BCM-15030

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: BCM-15030

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
10	Cyclophosphamide,Doxorubicin,Fluorouracil	Adjuvant	34.39	34.73	124 days	Not Reported	Not Applicable	Treatment Completed
20	Other,Tamoxifen	Metastatic	43.57	48.73	1883 days	Disease Progression	Not Applicable	Disease Progression
25	Anastrozole,Goserelin	Metastatic	49.06	49.15	33 days	Not Reported	Not Applicable	Side Effects
30	Megestrol acetate	Metastatic	49.23	55.48	2281 days	Disease Progression	Not Applicable	Disease Progression
35	Fulvestrant	Metastatic	55.48	56.73	456 days	Disease Progression	Not Applicable	Disease Progression
40	Letrozole	Metastatic	56.81	56.98	62 days	Disease Progression	Not Applicable	Disease Progression
45	Tamoxifen	Metastatic	57.06	57.15	33 days	Not Reported	Not Applicable	Treatment Completed
50	Oophorectomy	Prophylactic	57.15	57.15	1	Not Reported	Not Applicable	Treatment Completed
55	Anastrozole	Metastatic	57.16	57.73	208 days	Disease Progression	Not Applicable	Disease Progression
60	Everolimus,Exemestane	Metastatic	57.79	58.0	77 days	Not Reported	Not Applicable	Side Effects
65	Letrozole,Palbociclib	Metastatic	58.06	58.65	215 days	Disease Progression	Not Applicable	Disease Progression
70	Radiation Therapy	Metastatic	58.64	58.77	47 days	Not Reported	Not Applicable	Treatment Completed
75	Anastrozole	Metastatic	58.73	59.48	274 days	Disease Progression	Not Applicable	Disease Progression
80	Capecitabine	Metastatic	59.57	60.98	515 days	Disease Progression	Not Applicable	Disease Progression
95	High-dose estrogen	Metastatic	60.81	60.99	66 days	Disease Progression	Not Applicable	Disease Progression